Richter Transformation clinical trials at UCSF

1 research study open to eligible people

A Study of NX-1607 in Adults With Advanced Malignancies
open to eligible people ages 18 years and up
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
San Francisco, California and other locations

Last updated: August 28, 2023